L.C.E. SANDOZ 150/37.5/200 levodopa 150 mg, carbidopa (as carbidopa monohydrate) 37.5 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 150/37.5/200 levodopa 150 mg, carbidopa (as carbidopa monohydrate) 37.5 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: iron oxide yellow; croscarmellose sodium; povidone; magnesium stearate; polysorbate 80; glycerol; sucrose; iron oxide red; hypromellose; mannitol; titanium dioxide; maize starch - l.c.e. sandoz 150/37.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 125/31.25/200 levodopa 125 mg, carbidopa (as carbidopa monohydrate) 31.25 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 125/31.25/200 levodopa 125 mg, carbidopa (as carbidopa monohydrate) 31.25 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); levodopa, quantity: 125 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: glycerol; titanium dioxide; croscarmellose sodium; sucrose; magnesium stearate; polysorbate 80; mannitol; maize starch; povidone; iron oxide red; hypromellose - l.c.e. sandoz 125/31.25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 100/25/200 levodopa 100 mg, carbidopa (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 100/25/200 levodopa 100 mg, carbidopa (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg; levodopa, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; hypromellose; croscarmellose sodium; iron oxide red; titanium dioxide; povidone; magnesium stearate; glycerol; mannitol; sucrose - l.c.e. sandoz 75/18.75/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 50/12.5/200 levodopa 50 mg, carbidopa (as carbidopa monohydrate) 12.5 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 50/12.5/200 levodopa 50 mg, carbidopa (as carbidopa monohydrate) 12.5 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose; mannitol; titanium dioxide; magnesium stearate; povidone; maize starch; sucrose; iron oxide red; glycerol; iron oxide yellow; polysorbate 80; croscarmellose sodium - l.c.e. sandoz 50/12.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

APOMINE Intermittent apomorphine hydrochloride hemihydrate 30mg/3mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

apomine intermittent apomorphine hydrochloride hemihydrate 30mg/3ml injection cartridge

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - apomorphine injection is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

RURAL INLINE SOIL FUMIGANT Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rural inline soil fumigant

trical australia pty ltd - chloropicrin; 1,3-dichloropropene - liquid - chloropicrin gas active 333.0 g/kg; 1,3-dichloropropene solvent active 608.0 g/kg - mixed function pesticide - field crop | fruit crop | nursery crop | nut crop | vegetable crop | nursery plant - fusarium crown rot or wilt | nematode - soil borne plant parasitic | pythium spp. | rhizoctonia | soil borne diseases | suppression of annual grass weeds | symphylid | verticillium wilt | wireworm | garden centipedes | grease spot | pythium blight | soil fungi | symphylans | verticillium dahliae | verticillium soil fungus

COMTAN Israel - English - Ministry of Health

comtan

novartis israel ltd - entacapone - film coated tablets - entacapone 200 mg - entacapone - entacapone - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson`s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

BENZATROPINE INJECTION benzatropine mesilate 2mg in 2 mL, vial Australia - English - Department of Health (Therapeutic Goods Administration)

benzatropine injection benzatropine mesilate 2mg in 2 ml, vial

phebra pty ltd - benzatropine mesilate, quantity: 1 mg/ml - injection - excipient ingredients: sodium chloride; water for injections - benzatropine injection is recommended for all forms of parkinsonism - including arteriosclerotic, post-encephalitic, idiopathic, as well as drug induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. benzatropine injection often is helpful in patients who have become unresponsive to other agents. benzatropine injection is a powerful antichlolinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-drug-induced parkinsonism, partial control of symptoms is usually achieved.

APOMINE apomorphine hydrochloride hemihydrate 100 mg/20 mL solution for infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

apomine apomorphine hydrochloride hemihydrate 100 mg/20 ml solution for infusion vial

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; hydrochloric acid; water for injections - indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.